Lee Schwartzberg Selected Research

Dexamethasone (Maxidex)

10/2023	Work loss and activity impairment due to extended nausea and vomiting in patients with breast cancer receiving CINV prophylaxis.
1/2021	Efficacy of intravenous NEPA, a fixed NK1/5-HT3 receptor antagonist combination, for the prevention of chemotherapy-induced nausea and vomiting (CINV) during cisplatin- and anthracycline cyclophosphamide (AC)-based chemotherapy: A review of phase 3 studies.
1/2018	Recent advances in antiemetics: new formulations of 5HT3-receptor antagonists.
1/2017	NEPA, a fixed oral combination of netupitant and palonosetron, improves control of chemotherapy-induced nausea and vomiting (CINV) over multiple cycles of chemotherapy: results of a randomized, double-blind, phase 3 trial versus oral palonosetron.
1/2017	2016 Updated MASCC/ESMO Consensus Recommendations: Controlling nausea and vomiting with chemotherapy of low or minimal emetic potential.
1/2017	Prevention of chemotherapy-induced nausea: the role of neurokinin-1 (NK1) receptor antagonists.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Lee Schwartzberg Research Topics

Disease

43	Neoplasms (Cancer) 12/2023 - 04/2003
33	Nausea 12/2023 - 02/2006
32	Vomiting 12/2023 - 02/2006
30	Breast Neoplasms (Breast Cancer) 10/2023 - 12/2005
9	Neutropenia 01/2022 - 05/2004
8	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 06/2023 - 10/2006
7	Colorectal Neoplasms (Colorectal Cancer) 06/2023 - 03/2004
4	Disease Progression 10/2021 - 12/2013
4	Anemia 10/2010 - 11/2003
3	Exanthema (Rash) 01/2024 - 10/2006
3	Triple Negative Breast Neoplasms 10/2021 - 12/2014
3	Pain (Aches) 09/2018 - 04/2003
3	Febrile Neutropenia 09/2018 - 07/2014
2	Hypersensitivity (Allergy) 01/2021 - 01/2020
2	Lung Neoplasms (Lung Cancer) 01/2021 - 01/2017
2	Fatigue 12/2020 - 12/2013
1	Hyperglycemia 01/2024
1	COVID-19 11/2021
1	Pathologic Complete Response 10/2021
1	Uterine Neoplasms (Uterine Cancer) 01/2021
1	Injection Site Reaction 01/2021
1	Neoplasm Metastasis (Metastasis) 01/2021
1	Residual Neoplasm 01/2020
1	Anaphylaxis (Anaphylactic Shock) 01/2020

Drug/Important Bio-Agent (IBA)

18	AntiemeticsIBA 12/2023 - 02/2006
14	Hormones (Hormone)IBA 11/2022 - 07/2012
12	AnthracyclinesIBA 10/2023 - 06/2008
10	Palonosetron (Aloxi)FDA Link 04/2019 - 02/2006
8	Cyclophosphamide (Cytoxan)FDA LinkGeneric 10/2023 - 07/2015
8	human ERBB2 proteinIBA 01/2022 - 01/2013
6	netupitantIBA 10/2023 - 01/2017
6	Dexamethasone (Maxidex)FDA LinkGeneric 10/2023 - 01/2017
6	Estrogen ReceptorsIBA 10/2021 - 05/2018
6	taxaneIBA 01/2015 - 10/2006
5	Cisplatin (Platino)FDA LinkGeneric 01/2021 - 11/2009
4	EmeticsIBA 12/2023 - 02/2014
4	Biomarkers (Surrogate Marker)IBA 06/2023 - 05/2016
4	ErbB Receptors (EGF Receptor)IBA 10/2021 - 12/2013
4	Trastuzumab (Herceptin)FDA Link 01/2020 - 01/2014
4	eribulin FDA Link 06/2019 - 07/2014
4	PlatinumIBA 01/2019 - 10/2006
4	rolapitantIBA 01/2017 - 04/2016
4	Pemetrexed (MTA)FDA Link 12/2013 - 10/2009
4	Darbepoetin alfa (Aranesp)FDA Link 10/2010 - 11/2003
3	DNA (Deoxyribonucleic Acid)IBA 11/2022 - 05/2016
3	beta-Aminoethyl Isothiourea (AET)IBA 10/2021 - 12/2019
3	5-HT3 Serotonin Receptors (5 HT3 Receptor)IBA 01/2021 - 08/2011
3	Granisetron (Kytril)FDA LinkGeneric 01/2017 - 02/2014
3	Neurokinin-1 Receptor AntagonistsIBA 01/2017 - 02/2006
3	Aprepitant (Emend)FDA Link 01/2017 - 02/2006
3	Ondansetron (Zofran)FDA LinkGeneric 01/2017 - 02/2014
3	Monoclonal AntibodiesIBA 09/2015 - 04/2009
3	Carboplatin (JM8)FDA LinkGeneric 07/2015 - 11/2009
3	Gemcitabine FDA Link 12/2014 - 10/2009
3	Capecitabine (Xeloda)FDA Link 01/2014 - 06/2008
3	Bevacizumab (Avastin)FDA Link 12/2013 - 07/2008
2	RNA (Ribonucleic Acid)IBA 11/2021 - 03/2020
2	Progesterone Receptors (Progesterone Receptor)IBA 10/2021 - 02/2020
2	palbociclibIBA 10/2021 - 02/2020
2	Letrozole (Femara)FDA LinkGeneric 10/2021 - 02/2020
2	Oxaliplatin (Eloxatin)FDA LinkGeneric 01/2021 - 07/2008
2	Circulating Tumor DNAIBA 01/2020 - 05/2016
2	Lapatinib (GW572016)FDA Link 01/2020 - 01/2014
2	Colony-Stimulating Factors (Colony Stimulating Factor)IBA 09/2018 - 05/2004
2	Filgrastim (Neupogen)FDA Link 09/2018 - 05/2004
2	pegfilgrastim (Neulasta)FDA Link 09/2018 - 05/2004
2	Olanzapine (Zyprexa)FDA Link 01/2018 - 01/2017
2	Serotonin (5 Hydroxytryptamine)IBA 01/2018 - 01/2017
2	Cetuximab (Erbitux)FDA Link 09/2015 - 12/2013
2	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 12/2014 - 07/2014
2	Paclitaxel (Taxol)FDA LinkGeneric 01/2013 - 11/2009
2	Hemoglobins (Hemoglobin)IBA 10/2010 - 02/2004
2	Fluorouracil (Carac)FDA LinkGeneric 04/2009 - 03/2004
2	Epoetin Alfa (Epogen)FDA Link 12/2005 - 11/2003
1	Histamine Antagonists (Antihistamines)IBA 01/2024
1	AlpelisibIBA 01/2024
1	SteroidsIBA 01/2024
1	Antineoplastic Agents (Antineoplastics)IBA 12/2023
1	Estrogen Receptor alphaIBA 11/2022
1	Aromatase InhibitorsIBA 11/2022
1	LigandsIBA 11/2022
1	Peptide Hydrolases (Proteases)FDA Link 11/2021
1	Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)IBA 11/2021
1	enzalutamideIBA 12/2020
1	exemestane (Aromasin)FDA Link 12/2020
1	Androgen Receptors (Androgen Receptor)IBA 12/2020
1	Phenobarbital (Luminal)FDA Link 03/2020
1	pertuzumabIBA 01/2020
1	neratinibIBA 01/2020
1	fosaprepitant FDA Link 01/2020
1	Tyrosine Kinase InhibitorsIBA 01/2020
1	Immunoconjugates (Immunoconjugate)IBA 01/2020
1	NVP-BKM120IBA 11/2019

Therapy/Procedure

52	Drug Therapy (Chemotherapy) 12/2023 - 11/2003
43	Therapeutics 12/2023 - 10/2006
6	Adjuvant Chemotherapy 01/2022 - 07/2014
4	Drug Tapering 12/2014 - 06/2008
3	Precision Medicine 01/2021 - 01/2020
1	Hysterectomy 01/2021
1	Simple Mastectomy 02/2020